PPARγ Agonist Compositions for Addiction Relapse Prevention
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current treatments for substance addiction, such as alcoholism and nicotine addiction, have limited efficacy in preventing relapse and managing withdrawal symptoms, leading to high recurrence rates and significant social and economic impacts.
Innovation Solution
The use of PPARγ agonists, either alone or in combination with other therapeutic agents, to treat and prevent addiction by reducing addictive agent consumption and relapse, including thiazolidinediones like pioglitazone and naltrexone, which work synergistically to address addiction and withdrawal symptoms.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If conventional treatments such as naltrexone, acamprosate, disulfiram, and other medications are used for alcohol abuse, then some therapeutic effect is achieved, but the efficacy is insufficient and prognosis remains poor
Solution Approach 1:
The patent combines multiple therapeutic agents with different mechanisms of action into a single treatment regimen. Specifically, it merges naltrexone (opioid antagonist), acamprosate (glutamate modulator), and disulfiram (aldehyde dehydrogenase inhibitor) to create a multi-target approach that addresses multiple aspects of alcohol addiction simultaneously, thereby improving overall therapeutic efficacy and prognosis
2Reliability
If nicotine replacement products, anti-depressants, anti-hypersensitives, and behavioural therapy are used for nicotine addiction, then moderate success is achieved in preventing relapse, but the failure rate remains high
Solution Approach 1:
The patent employs a composite therapeutic approach by combining pharmacological agents (nicotine replacement products, anti-depressants, anti-hypersensitives) with behavioural therapy interventions. This composite strategy creates a multi-faceted treatment that addresses both the physiological and psychological aspects of nicotine addiction, aiming to reduce the high failure rate associated with single-modality treatments
3Reliability
If opioid receptor antagonists are used to block the effect of agonists in opiate addiction, then the effect of the agonist is blocked, but withdrawal symptoms are precipitated and therapeutic use is associated with increased accidental overdosing and increased lethality
Solution Approach 1:
The patent applies preliminary anti-action by administering opioid receptor antagonists in a controlled manner to block agonist effects before they can cause harm, while simultaneously implementing monitoring and support measures to prevent withdrawal symptoms and accidental overdosing. This proactive approach aims to neutralize the harmful effects of opiate addiction while minimizing the risks associated with antagonist therapy
Data Source
AI summary
The present invention relates to methods of treating or preventing addiction and relapse use of addictive agents, and treating or preventing addictive or compulsive behavior and relapse practice of an addictive behavior or compulsion, by administering a peroxisome proliferator-activated receptor gamma (PPARγ) agonist, alone or in combination with another therapeutic agent, such as, for example, an opioid receptor antagonist or an antidepressant, or an addictive agent, such as, for example, an opioid agonist. The present invention also includes pharmaceutical compositions for treating or preventing addiction or relapse that include a PPARγ agonist and one or more other therapeutic or addictive agents, as well as unit dosage forms of such pharmaceutical compositions, which contain a dosage effective in treating or preventing addiction or relapse. The methods and compositions of the invention are useful in the treatment or prevention of addiction to any agent, including alcohol, nicotine, marijuana, cocaine, and amphetamines, as well as compulsive and addictive behaviors, including pathological gambling and pathological overeating.